Fate Therapeutics Inc. (FATE) NASDAQ
$5.64 (0.13) (-2.25%)
Market Cap: $559.70M
As of 04/15/24 04:00 PM EDT. Market closed.
Fate Therapeutics Inc. (FATE)
NASDAQ
$5.64
(0.13) (-2.25%)
Market Cap: $559.70M
As of 04/15/24 04:00 PM EDT. Market closed.
Add to Portfolio
fate therapeutics is applying leading expertise in stem cell biology and conventional drug discovery to develop small molecule and biologic drugs that: 1) activate stem cells in the body to stimulate healing and repair or block cancer growth; and 2) create and differentiate "pharmaceutical grade"? ips cells to enable their use in drug discovery and development, disease modeling, and eventually ... read more
fate therapeutics is applying leading expertise in stem cell biology and conventional drug discovery to develop small molecule and biologic drugs that: 1) activate stem cells in the body to stimulate healing and repair or block cancer growth; and 2) create and differentiate "pharmaceutical grade"? ips cells to enable their use in drug discovery and development, disease modeling, and eventually personalized cell therapies. the company’s approach has broad therapeutic potential in areas such as regenerative medicine, hematological diseases, metastatic cancer, traumatic injury and degenerative diseases. read less
COMPANY PROFILE
Sector
Professional, Scientific, and Technical Services
Industry
Research and Development in Biotechnology (except Nanobiotechnology)
CEO
John Wolchko
Full Time Employees
482
CEO Compensation (Base)
$516,000
CEO Compensation (Total)
$3.53M
Sector
Professional, Scientific, and Technical Services
Industry
Research and Development in Biotechnology (except Nanobiotechnology)
CEO
John Wolchko
Full Time Employees
482
CEO Compensation (Base)
$516,000
CEO Compensation (Total)
$3.53M
Address
3535 General Atomics Ct Ste 200, California, San Diego, 92121-1140.
PRICE CHART FOR FATE THERAPEUTICS INC
From:
To:
NEWS
INSIDEARBITRAGE ARTICLES
KEY STATS
Open
-
Previous Close
$5.77
Days Range
$5.40 - $5.95
52 week range
$1.63 - $8.83
Volume
1
Avg. Volume (30 days)
2,197,532
Market Cap
$559.70M
Dividend Yield
-
P/E
(3.48)
Shares Outstanding
99,237,508
Open
-
Previous Close
$5.77
Days Range
$5.40 - $5.95
52 week range
$1.63 - $8.83
Volume
1
Avg. Volume (30 days)
2,197,532
Market Cap
$559.70M
Dividend Yield
-
P/E
(3.48)
Shares Outstanding
99,237,508
FINANCIAL STATEMENTS FOR FATE THERAPEUTICS INC
LOADING...
Open in: 
Open in:
INSIDER TRANSACTIONS FOR FATE THERAPEUTICS INC
| Owner | Relationship | Date | Transaction | Cost | # Shares | Value($) | Total Shares | Form 4 |
| Dulac Edward J III | Chief Financial Officer | Mar 04, 2024 | Sale | $7.77 | 2,447 | 19,013 | 101,479 | Mar 05, 2024, 04:24 PM |
| Dulac Edward J III | Chief Financial Officer | Jan 29, 2024 | Sale | $5.00 | 1,849 | 9,245 | 103,926 | Jan 30, 2024, 04:01 PM |
| TAHL CINDY | General Counsel and Secretary | Jan 09, 2024 | Sale | $4.37 | 10,874 | 47,519 | 142,361 | Jan 10, 2024, 04:30 PM |
| Valamehr Bahram | Chief R&D Officer | Jan 09, 2024 | Sale | $4.38 | 11,271 | 49,367 | 158,069 | Jan 10, 2024, 04:30 PM |
| Wolchko J Scott | President and CEO | Jan 09, 2024 | Sale | $4.37 | 14,391 | 62,889 | 371,248 | Jan 10, 2024, 04:29 PM |
| Dulac Edward J III | Chief Financial Officer | Jan 09, 2024 | Sale | $4.37 | 7,028 | 30,712 | 105,775 | Jan 10, 2024, 04:29 PM |
| Dulac Edward J III | Chief Financial Officer | Jan 02, 2024 | Sale | $3.66 | 5,182 | 18,966 | 112,803 | Jan 03, 2024, 04:03 PM |
| Redmile Group, LLC | Director | Dec 26, 2023 | Option Exercise | $3.72 | 3,310,740 | 12,315,953 | 13,135,758 | Dec 28, 2023, 09:30 PM |
| Redmile Group, LLC | Director | Dec 26, 2023 | Buy | $3.72 | 44,630 | 166,024 | 13,180,388 | Dec 28, 2023, 09:30 PM |
| Dulac Edward J III | Chief Financial Officer | Dec 18, 2023 | Sale | $3.50 | 1,585 | 5,548 | 117,985 | Dec 19, 2023, 04:01 PM |
| TAHL CINDY | General Counsel and Secretary | Nov 09, 2023 | Sale | $2.40 | 24,363 | 58,471 | 153,235 | Nov 13, 2023, 04:01 PM |
| Dulac Edward J III | Chief Financial Officer | Aug 18, 2023 | Sale | $2.80 | 4,718 | 13,210 | 119,570 | Aug 21, 2023, 04:02 PM |
| Xu Yuan | Director | Aug 04, 2023 | Sale | $3.71 | 632 | 2,345 | 9,302 | Aug 07, 2023, 04:01 PM |
| Powl Brian T. | Chief Commercial Officer | Jul 05, 2023 | Sale | $4.87 | 3,854 | 18,769 | 41,146 | Jul 06, 2023, 05:19 PM |
| Dulac Edward J III | Chief Financial Officer | Jul 05, 2023 | Sale | $4.83 | 5,182 | 25,029 | 124,288 | Jul 06, 2023, 05:18 PM |
| Xu Yuan | Director | Jun 14, 2023 | Sale | $5.58 | 3,460 | 19,307 | 9,934 | Jun 15, 2023, 04:05 PM |
| Redmile Group, LLC | Director | Apr 21, 2023 | Buy | $6.18 | 256,639 | 1,586,029 | 13,135,758 | Apr 21, 2023, 09:55 PM |
| Redmile Group, LLC | Director | Apr 20, 2023 | Buy | $5.99 | 20,000 | 119,800 | 12,879,119 | Apr 21, 2023, 09:55 PM |
| Chu Yu-Waye | Chief Medical Officer | Apr 18, 2023 | Sale | $6.57 | 2,532 | 16,648 | 142,993 | Apr 19, 2023, 04:07 PM |
| Redmile Group, LLC | Director | Apr 14, 2023 | Option Exercise | $5.84 | 10,984,770 | 64,151,058 | 12,833,419 | Apr 17, 2023, 09:30 PM |
| Redmile Group, LLC | Director | Apr 14, 2023 | Buy | $6.00 | 25,700 | 154,200 | 12,859,119 | Apr 17, 2023, 09:30 PM |
| Redmile Group, LLC | Director | Apr 14, 2023 | Sale | $5.84 | 302,339 | 1,765,660 | 12,833,419 | Apr 17, 2023, 09:30 PM |
| MENDLEIN JOHN | Director | Jan 19, 2023 | Option Exercise | $1.37 | 28,461 | 38,992 | 311,231 | Jan 20, 2023, 04:14 PM |
| MENDLEIN JOHN | Director | Jan 13, 2023 | Buy | $5.43 | 36,631 | 198,906 | 282,770 | Jan 13, 2023, 06:20 PM |
| MENDLEIN JOHN | Director | Jan 11, 2023 | Buy | $5.67 | 88,048 | 499,232 | 246,139 | Jan 13, 2023, 06:20 PM |
| Valamehr Bahram | Chief R&D Officer | Jan 12, 2023 | Option Exercise | $1.37 | 423 | 580 | 169,340 | Jan 13, 2023, 04:02 PM |
| Wolchko J Scott | President and CEO | Jan 10, 2023 | Sale | $5.24 | 45,907 | 240,553 | 385,639 | Jan 11, 2023, 04:09 PM |
| Valamehr Bahram | Chief R&D Officer | Jan 10, 2023 | Sale | $5.24 | 10,917 | 57,205 | 168,917 | Jan 11, 2023, 04:08 PM |
| TAHL CINDY | General Counsel and Secretary | Jan 10, 2023 | Sale | $5.24 | 11,553 | 60,538 | 177,598 | Jan 11, 2023, 04:08 PM |
| Plavsic Mark | Chief Technical Officer | Jan 10, 2023 | Sale | $5.24 | 3,418 | 17,910 | 123,705 | Jan 11, 2023, 04:07 PM |
| Dulac Edward J III | Chief Financial Officer | Jan 10, 2023 | Sale | $5.24 | 7,331 | 38,414 | 129,470 | Jan 11, 2023, 04:06 PM |
| Chu Yu-Waye | Chief Medical Officer | Jan 10, 2023 | Sale | $5.24 | 7,825 | 41,003 | 143,208 | Jan 11, 2023, 04:05 PM |
| Dulac Edward J III | Chief Financial Officer | Aug 18, 2022 | Sale | $29.81 | 5,135 | 153,051 | 137,233 | Aug 19, 2022, 06:58 PM |
| Wolchko J Scott | President and CEO | Jul 22, 2022 | Option Exercise | $2.70 | 6,246 | 16,864 | 437,792 | Jul 25, 2022, 06:18 PM |
| Wolchko J Scott | President and CEO | Jul 21, 2022 | Option Exercise | $2.70 | 30,000 | 81,000 | 461,546 | Jul 25, 2022, 06:18 PM |
| Wolchko J Scott | President and CEO | Jul 22, 2022 | Sale | $32.08 | 6,246 | 200,356 | 434,869 | Jul 25, 2022, 06:18 PM |
| Wolchko J Scott | President and CEO | Jul 21, 2022 | Sale | $32.88 | 30,000 | 986,361 | 450,717 | Jul 25, 2022, 06:18 PM |
| Valamehr Bahram | Chief R&D Officer | Jul 07, 2022 | Option Exercise | $2.73 | 17,158 | 46,841 | 196,992 | Jul 08, 2022, 04:51 PM |
| Valamehr Bahram | Chief R&D Officer | Jul 07, 2022 | Sale | $30.23 | 17,158 | 518,686 | 179,834 | Jul 08, 2022, 04:51 PM |
| Valamehr Bahram | Chief R&D Officer | Jul 06, 2022 | Option Exercise | $3.27 | 7,842 | 25,629 | 187,676 | Jul 07, 2022, 04:04 PM |
| Valamehr Bahram | Chief R&D Officer | Jul 06, 2022 | Sale | $30.07 | 7,842 | 235,809 | 179,834 | Jul 07, 2022, 04:04 PM |
| Agarwal Shefali | Director | Jun 07, 2022 | Sale | $21.89 | 841 | 18,409 | 1,840 | Jun 08, 2022, 04:03 PM |
| MENDLEIN JOHN | Director | Jun 03, 2022 | Sale | $22.79 | 1,364 | 31,086 | 158,091 | Jun 06, 2022, 04:49 PM |
| Jooss Karin | Director | Jun 03, 2022 | Sale | $22.82 | 1,483 | 33,842 | 1,198 | Jun 06, 2022, 04:48 PM |
| HERSHBERG ROBERT | Director | Jun 03, 2022 | Sale | $22.75 | 672 | 15,288 | 2,009 | Jun 06, 2022, 04:45 PM |
| COUGHLIN TIMOTHY | Director | Jun 03, 2022 | Sale | $22.81 | 1,439 | 32,824 | 57,632 | Jun 06, 2022, 04:43 PM |
| Agarwal Shefali | Director | Jun 03, 2022 | Sale | $22.80 | 807 | 18,400 | 1,874 | Jun 06, 2022, 04:40 PM |
| TAHL CINDY | General Counsel and Secretary | Jun 01, 2022 | Option Exercise | $6.55 | 25,000 | 163,750 | 214,151 | Jun 02, 2022, 04:04 PM |
| TAHL CINDY | General Counsel and Secretary | Jun 01, 2022 | Sale | $22.96 | 25,000 | 574,000 | 189,151 | Jun 02, 2022, 04:04 PM |
| Wolchko J Scott | President and CEO | Apr 21, 2022 | Option Exercise | $2.70 | 30,000 | 81,000 | 461,546 | Apr 25, 2022, 04:11 PM |
| Wolchko J Scott | President and CEO | Apr 22, 2022 | Option Exercise | $2.70 | 10,000 | 27,000 | 441,546 | Apr 25, 2022, 04:11 PM |
| Wolchko J Scott | President and CEO | Apr 22, 2022 | Sale | $34.59 | 10,000 | 345,911 | 432,384 | Apr 25, 2022, 04:11 PM |
| Wolchko J Scott | President and CEO | Apr 21, 2022 | Sale | $35.00 | 30,000 | 1,049,881 | 438,831 | Apr 25, 2022, 04:11 PM |
| Chu Yu-Waye | Chief Medical Officer | Apr 19, 2022 | Sale | $35.37 | 4,062 | 143,673 | 151,033 | Apr 21, 2022, 04:04 PM |
| Valamehr Bahram | Chief R&D Officer | Mar 14, 2022 | Option Exercise | $2.73 | 25,000 | 68,250 | 204,834 | Mar 15, 2022, 04:27 PM |
| Valamehr Bahram | Chief R&D Officer | Mar 14, 2022 | Sale | $31.07 | 25,000 | 776,733 | 188,156 | Mar 15, 2022, 04:27 PM |
| MENDLEIN JOHN | Director | Mar 10, 2022 | Option Exercise | $1.63 | 31,562 | 51,446 | 191,017 | Mar 11, 2022, 04:58 PM |
| MENDLEIN JOHN | Director | Mar 10, 2022 | Sale | $35.02 | 31,562 | 1,105,200 | 171,524 | Mar 11, 2022, 04:58 PM |
| Wolchko J Scott | President and CEO | Jan 20, 2022 | Option Exercise | $2.70 | 30,000 | 81,000 | 461,546 | Feb 04, 2022, 05:59 PM |
| Wolchko J Scott | President and CEO | Jan 21, 2022 | Option Exercise | $2.70 | 10,000 | 27,000 | 441,546 | Jan 24, 2022, 04:36 PM |
| Wolchko J Scott | President and CEO | Jan 20, 2022 | Option Exercise | $2.73 | 30,000 | 81,900 | 461,546 | Jan 24, 2022, 04:36 PM |
| Wolchko J Scott | President and CEO | Jan 21, 2022 | Sale | $38.02 | 10,000 | 380,200 | 431,546 | Jan 24, 2022, 04:36 PM |
| Wolchko J Scott | President and CEO | Jan 20, 2022 | Sale | $40.21 | 30,000 | 1,206,300 | 431,546 | Jan 24, 2022, 04:36 PM |
| Wolchko J Scott | President and CEO | Jan 11, 2022 | Sale | $48.68 | 14,566 | 709,027 | 436,065 | Jan 13, 2022, 04:09 PM |
| TAHL CINDY | General Counsel and Secretary | Jan 11, 2022 | Sale | $48.53 | 5,419 | 262,975 | 156,385 | Jan 13, 2022, 04:08 PM |
| Valamehr Bahram | Chief R&D Officer | Jan 11, 2022 | Sale | $48.50 | 4,570 | 221,655 | 146,950 | Jan 13, 2022, 04:07 PM |
| Dulac Edward J III | Chief Financial Officer | Jan 11, 2022 | Sale | $48.45 | 1,770 | 85,757 | 109,024 | Jan 13, 2022, 04:06 PM |
| Chu Yu-Waye | Senior VP Clinical Development | Jan 11, 2022 | Sale | $48.51 | 3,965 | 192,340 | 122,211 | Jan 13, 2022, 04:05 PM |
| Wolchko J Scott | President and CEO | Jan 10, 2022 | Sale | $46.86 | 34,156 | 1,600,534 | 467,107 | Jan 12, 2022, 04:07 PM |
| TAHL CINDY | General Counsel and Secretary | Jan 10, 2022 | Sale | $46.43 | 7,738 | 359,313 | 161,911 | Jan 12, 2022, 04:06 PM |
| Valamehr Bahram | Chief R&D Officer | Jan 10, 2022 | Sale | $46.38 | 5,596 | 259,558 | 151,453 | Jan 12, 2022, 04:05 PM |
| TAHL CINDY | General Counsel and Secretary | Jan 03, 2022 | Option Exercise | $6.55 | 50,000 | 327,500 | 219,006 | Jan 04, 2022, 04:03 PM |
| TAHL CINDY | General Counsel and Secretary | Jan 03, 2022 | Sale | $59.34 | 50,000 | 2,966,853 | 214,579 | Jan 04, 2022, 04:03 PM |
| Dulac Edward J III | Chief Financial Officer | Dec 20, 2021 | Option Exercise | $35.52 | 14,437 | 512,802 | 126,381 | Dec 21, 2021, 04:08 PM |
| Dulac Edward J III | Chief Financial Officer | Dec 20, 2021 | Sale | $60.00 | 15,977 | 958,620 | 110,404 | Dec 21, 2021, 04:08 PM |
| Valamehr Bahram | Chief R&D Officer | Dec 13, 2021 | Option Exercise | $2.73 | 25,000 | 68,250 | 181,698 | Dec 14, 2021, 04:18 PM |
| Valamehr Bahram | Chief R&D Officer | Dec 13, 2021 | Sale | $47.66 | 25,000 | 1,191,406 | 179,598 | Dec 14, 2021, 04:18 PM |
| Chu Yu-Waye | Senior VP Clinical Development | Dec 10, 2021 | Option Exercise | $16.32 | 7,500 | 122,400 | 133,258 | Dec 13, 2021, 05:53 PM |
| Chu Yu-Waye | Senior VP Clinical Development | Dec 10, 2021 | Sale | $51.46 | 7,500 | 385,948 | 131,161 | Dec 13, 2021, 05:53 PM |
| Wolchko J Scott | President and CEO | Nov 18, 2021 | Option Exercise | $2.70 | 20,000 | 54,000 | 413,793 | Nov 22, 2021, 05:45 PM |
| Wolchko J Scott | President and CEO | Nov 18, 2021 | Sale | $54.27 | 20,000 | 1,085,400 | 393,793 | Nov 22, 2021, 05:45 PM |
| Wolchko J Scott | President and CEO | Oct 22, 2021 | Option Exercise | $3.06 | 30,000 | 91,670 | 423,793 | Oct 25, 2021, 04:04 PM |
| Wolchko J Scott | President and CEO | Oct 21, 2021 | Option Exercise | $2.73 | 30,000 | 81,900 | 423,793 | Oct 25, 2021, 04:04 PM |
| Wolchko J Scott | President and CEO | Oct 22, 2021 | Sale | $58.88 | 30,000 | 1,766,400 | 393,793 | Oct 25, 2021, 04:04 PM |
| Wolchko J Scott | President and CEO | Oct 21, 2021 | Sale | $60.22 | 30,000 | 1,806,560 | 408,558 | Oct 25, 2021, 04:04 PM |
| TAHL CINDY | General Counsel and Secretary | Oct 01, 2021 | Option Exercise | $6.55 | 50,000 | 327,500 | 158,048 | Oct 04, 2021, 04:12 PM |
| TAHL CINDY | General Counsel and Secretary | Oct 01, 2021 | Sale | $58.83 | 50,000 | 2,941,462 | 141,736 | Oct 04, 2021, 04:12 PM |
| Dulac Edward J III | Chief Financial Officer | Sep 28, 2021 | Option Exercise | $35.52 | 17,325 | 615,384 | 71,864 | Sep 30, 2021, 04:14 PM |
| Dulac Edward J III | Chief Financial Officer | Sep 28, 2021 | Sale | $62.53 | 19,460 | 1,216,834 | 52,404 | Sep 30, 2021, 04:14 PM |
| Valamehr Bahram | Chief Development Officer | Sep 13, 2021 | Option Exercise | $2.73 | 25,000 | 68,250 | 120,740 | Sep 14, 2021, 04:01 PM |
| Valamehr Bahram | Chief Development Officer | Sep 13, 2021 | Sale | $66.29 | 25,000 | 1,657,257 | 104,931 | Sep 14, 2021, 04:01 PM |
| Wolchko J Scott | President and CEO | Aug 19, 2021 | Option Exercise | $4.84 | 20,000 | 96,700 | 413,793 | Aug 20, 2021, 04:02 PM |
| Wolchko J Scott | President and CEO | Aug 19, 2021 | Sale | $88.01 | 20,000 | 1,760,204 | 393,793 | Aug 20, 2021, 04:02 PM |
| Dulac Edward J III | Chief Financial Officer | Aug 19, 2021 | Sale | $88.26 | 3,474 | 306,602 | 56,076 | Aug 20, 2021, 04:01 PM |
| Wolchko J Scott | President and CEO | Jul 23, 2021 | Option Exercise | $4.14 | 30,000 | 124,100 | 423,793 | Jul 26, 2021, 04:05 PM |
| Wolchko J Scott | President and CEO | Jul 22, 2021 | Option Exercise | $2.73 | 30,000 | 81,900 | 423,793 | Jul 26, 2021, 04:05 PM |
| Wolchko J Scott | President and CEO | Jul 23, 2021 | Sale | $85.28 | 30,000 | 2,558,538 | 393,793 | Jul 26, 2021, 04:05 PM |
| Wolchko J Scott | President and CEO | Jul 22, 2021 | Sale | $86.05 | 30,000 | 2,581,575 | 417,166 | Jul 26, 2021, 04:05 PM |
| TAHL CINDY | General Counsel and Secretary | Jul 01, 2021 | Option Exercise | $5.64 | 55,534 | 313,242 | 163,582 | Jul 02, 2021, 07:08 PM |
| TAHL CINDY | General Counsel and Secretary | Jul 01, 2021 | Sale | $85.24 | 55,534 | 4,733,743 | 163,482 | Jul 02, 2021, 07:08 PM |
| Chu Yu-Waye | Senior VP Clinical Development | Apr 16, 2021 | Sale | $83.30 | 3,275 | 272,809 | 67,200 | Apr 20, 2021, 04:00 PM |
| TAHL CINDY | See Remarks | Apr 01, 2021 | Option Exercise | $3.21 | 30,000 | 96,199 | 138,048 | Apr 02, 2021, 06:03 PM |
| TAHL CINDY | See Remarks | Apr 01, 2021 | Sale | $83.81 | 30,000 | 2,514,329 | 137,048 | Apr 02, 2021, 06:03 PM |
| Valamehr Bahram | Chief Development Officer | Mar 15, 2021 | Option Exercise | $2.90 | 25,000 | 72,500 | 120,740 | Mar 16, 2021, 04:05 PM |
| Valamehr Bahram | Chief Development Officer | Mar 15, 2021 | Sale | $92.35 | 25,000 | 2,308,772 | 116,783 | Mar 16, 2021, 04:05 PM |
| Shoemaker Daniel D | Chief Scientific Officer | Mar 08, 2021 | Sale | $81.74 | 25,000 | 2,043,428 | 94,722 | Mar 09, 2021, 04:02 PM |
| Wolchko J Scott | President and CEO | Feb 18, 2021 | Option Exercise | $6.62 | 20,000 | 132,400 | 413,793 | Feb 19, 2021, 04:07 PM |
| Wolchko J Scott | President and CEO | Feb 18, 2021 | Sale | $102.01 | 20,000 | 2,040,256 | 412,392 | Feb 19, 2021, 04:07 PM |
| Wolchko J Scott | President and CEO | Jan 21, 2021 | Option Exercise | $2.73 | 30,000 | 81,900 | 423,793 | Jan 22, 2021, 06:23 PM |
| Wolchko J Scott | President and CEO | Jan 22, 2021 | Option Exercise | $5.32 | 30,000 | 159,700 | 423,793 | Jan 22, 2021, 06:23 PM |
| Wolchko J Scott | President and CEO | Jan 22, 2021 | Sale | $98.29 | 30,000 | 2,948,613 | 411,026 | Jan 22, 2021, 06:23 PM |
| Wolchko J Scott | President and CEO | Jan 21, 2021 | Sale | $103.05 | 30,000 | 3,091,361 | 421,253 | Jan 22, 2021, 06:23 PM |
| TAHL CINDY | General Counsel and Secretary | Jan 19, 2021 | Option Exercise | $2.90 | 35,000 | 101,500 | 125,035 | Jan 21, 2021, 07:08 PM |
| TAHL CINDY | General Counsel and Secretary | Jan 19, 2021 | Sale | $114.76 | 35,000 | 4,016,643 | 109,200 | Jan 21, 2021, 07:08 PM |
| Wolchko J Scott | President and CEO | Jan 11, 2021 | Sale | $110.81 | 8,587 | 951,556 | 355,634 | Jan 12, 2021, 08:41 PM |
| Wolchko J Scott | President and CEO | Jan 08, 2021 | Sale | $117.10 | 60,820 | 7,122,217 | 393,065 | Jan 12, 2021, 08:41 PM |
| Valamehr Bahram | Chief Development Officer | Jan 11, 2021 | Sale | $110.81 | 3,254 | 360,588 | 79,649 | Jan 12, 2021, 08:40 PM |
| Valamehr Bahram | Chief Development Officer | Jan 08, 2021 | Sale | $117.10 | 6,230 | 729,552 | 84,455 | Jan 12, 2021, 08:40 PM |
| TAHL CINDY | General Counsel and Secretary | Jan 08, 2021 | Sale | $117.10 | 6,229 | 729,434 | 96,763 | Jan 12, 2021, 08:39 PM |
| TAHL CINDY | General Counsel and Secretary | Jan 11, 2021 | Sale | $110.81 | 3,254 | 360,587 | 91,957 | Jan 12, 2021, 08:39 PM |
| Shoemaker Daniel D | Chief Scientific Officer | Jan 11, 2021 | Sale | $110.81 | 3,253 | 360,477 | 85,530 | Jan 12, 2021, 08:38 PM |
| Shoemaker Daniel D | Chief Scientific Officer | Jan 08, 2021 | Sale | $117.10 | 6,229 | 729,434 | 90,336 | Jan 12, 2021, 08:38 PM |
| Redmile Group, LLC | Director | Jan 08, 2021 | Buy | $85.50 | 327,485 | 27,999,968 | 12,957,222 | Jan 12, 2021, 04:16 PM |
| Wolchko J Scott | President and CEO | Dec 17, 2020 | Option Exercise | $6.62 | 20,000 | 132,400 | 439,969 | Dec 18, 2020, 04:01 PM |
| Wolchko J Scott | President and CEO | Dec 17, 2020 | Sale | $91.82 | 20,000 | 1,836,352 | 436,801 | Dec 18, 2020, 04:01 PM |
| Valamehr Bahram | Chief Development Officer | Dec 14, 2020 | Option Exercise | $2.90 | 25,000 | 72,500 | 112,211 | Dec 15, 2020, 04:01 PM |
| Valamehr Bahram | Chief Development Officer | Dec 14, 2020 | Sale | $97.78 | 25,000 | 2,444,477 | 110,398 | Dec 15, 2020, 04:01 PM |
| Shoemaker Daniel D | Chief Scientific Officer | Nov 16, 2020 | Sale | $51.83 | 25,000 | 1,295,746 | 113,159 | Nov 16, 2020, 05:12 PM |
| Wolchko J Scott | President and CEO | Nov 12, 2020 | Option Exercise | $2.73 | 30,000 | 81,900 | 449,969 | Nov 16, 2020, 04:02 PM |
| Wolchko J Scott | President and CEO | Nov 13, 2020 | Option Exercise | $5.73 | 30,000 | 172,007 | 430,123 | Nov 16, 2020, 04:02 PM |
| Wolchko J Scott | President and CEO | Nov 12, 2020 | Sale | $52.72 | 30,000 | 1,581,524 | 434,767 | Nov 16, 2020, 04:02 PM |
| Wolchko J Scott | President and CEO | Nov 13, 2020 | Sale | $51.03 | 30,000 | 1,530,900 | 419,969 | Nov 16, 2020, 04:02 PM |
| TAHL CINDY | General Counsel and Secretary | Nov 05, 2020 | Option Exercise | $2.82 | 19,282 | 54,340 | 118,800 | Nov 06, 2020, 04:02 PM |
| TAHL CINDY | General Counsel and Secretary | Nov 04, 2020 | Option Exercise | $2.73 | 51,519 | 140,647 | 151,037 | Nov 06, 2020, 04:02 PM |
| TAHL CINDY | General Counsel and Secretary | Nov 05, 2020 | Sale | $50.63 | 19,282 | 976,252 | 102,118 | Nov 06, 2020, 04:02 PM |
| TAHL CINDY | General Counsel and Secretary | Nov 04, 2020 | Sale | $50.41 | 51,519 | 2,597,140 | 99,518 | Nov 06, 2020, 04:02 PM |
| TAHL CINDY | General Counsel and Secretary | Oct 16, 2020 | Option Exercise | $2.73 | 29,199 | 79,713 | 128,717 | Oct 20, 2020, 04:01 PM |
| TAHL CINDY | General Counsel and Secretary | Oct 16, 2020 | Sale | $50.25 | 29,199 | 1,467,212 | 99,518 | Oct 20, 2020, 04:01 PM |
| TAHL CINDY | General Counsel and Secretary | Oct 01, 2020 | Option Exercise | $2.73 | 35,000 | 95,550 | 134,518 | Oct 02, 2020, 12:00 AM |
| TAHL CINDY | General Counsel and Secretary | Oct 01, 2020 | Sale | $40.74 | 35,000 | 1,426,065 | 112,761 | Oct 02, 2020, 12:00 AM |
| Valamehr Bahram | Chief Development Officer | Sep 14, 2020 | Option Exercise | $2.75 | 25,000 | 68,778 | 112,211 | Sep 16, 2020, 04:02 PM |
| Valamehr Bahram | Chief Development Officer | Sep 14, 2020 | Sale | $36.28 | 25,000 | 907,024 | 111,611 | Sep 16, 2020, 04:02 PM |
| Shoemaker Daniel D | Chief Scientific Officer | Sep 14, 2020 | Sale | $36.30 | 25,000 | 907,540 | 141,691 | Sep 16, 2020, 04:01 PM |
| Redmile Group, LLC | Director | Jun 11, 2020 | Buy | $28.31 | 1,412,928 | 39,999,991 | 12,629,737 | Jun 17, 2020, 08:25 PM |
| RASTETTER WILLIAM H | Director | Mar 30, 2020 | Option Exercise | $1.37 | 28,461 | 38,992 | 28,461 | Mar 31, 2020, 04:01 PM |
| Valamehr Bahram | Chief Development Officer | Feb 03, 2020 | Option Exercise | $1.69 | 1,153 | 1,949 | 87,211 | Feb 04, 2020, 12:00 AM |
| Wolchko J Scott | President and CEO | Jan 30, 2020 | Option Exercise | $2.70 | 25,000 | 67,500 | 444,969 | Feb 03, 2020, 04:01 PM |
| Wolchko J Scott | President and CEO | Jan 30, 2020 | Sale | $25.45 | 25,000 | 636,303 | 419,969 | Feb 03, 2020, 04:01 PM |
| Valamehr Bahram | Chief Development Officer | Jan 08, 2020 | Sale | $20.69 | 5,700 | 117,947 | 86,058 | Jan 10, 2020, 04:03 PM |
| TAHL CINDY | General Counsel and Secretary | Jan 08, 2020 | Sale | $20.72 | 5,700 | 118,085 | 99,518 | Jan 10, 2020, 04:02 PM |
| Shoemaker Daniel D | Chief Scientific Officer | Jan 08, 2020 | Sale | $20.70 | 5,700 | 117,986 | 143,091 | Jan 10, 2020, 04:01 PM |
| Shoemaker Daniel D | Chief Scientific Officer | Dec 30, 2019 | Option Exercise | $2.90 | 25,000 | 72,500 | 148,791 | Jan 02, 2020, 04:01 PM |
| Shoemaker Daniel D | Chief Scientific Officer | Dec 30, 2019 | Sale | $19.50 | 25,000 | 487,427 | 123,891 | Jan 02, 2020, 04:01 PM |
| Wolchko J Scott | President and CEO | Dec 19, 2019 | Option Exercise | $2.70 | 25,000 | 67,500 | 378,969 | Dec 23, 2019, 04:02 PM |
| Wolchko J Scott | President and CEO | Dec 20, 2019 | Option Exercise | $2.70 | 25,000 | 67,500 | 378,969 | Dec 23, 2019, 04:02 PM |
| Wolchko J Scott | President and CEO | Dec 20, 2019 | Sale | $20.17 | 25,000 | 504,157 | 353,969 | Dec 23, 2019, 04:02 PM |
| Wolchko J Scott | President and CEO | Dec 19, 2019 | Sale | $20.08 | 25,000 | 501,897 | 353,969 | Dec 23, 2019, 04:02 PM |
| Wolchko J Scott | President and CEO | Oct 15, 2019 | Sale | $14.44 | 21,017 | 303,458 | 353,969 | Oct 16, 2019, 04:07 PM |
| Valamehr Bahram | Chief Development Officer | Oct 15, 2019 | Sale | $14.18 | 6,200 | 87,891 | 66,758 | Oct 16, 2019, 04:06 PM |
| TAHL CINDY | General Counsel and Secretary | Oct 15, 2019 | Sale | $14.24 | 10,200 | 145,292 | 80,218 | Oct 16, 2019, 04:05 PM |
| Shoemaker Daniel D | Chief Scientific Officer | Oct 15, 2019 | Sale | $14.29 | 11,800 | 168,593 | 123,791 | Oct 16, 2019, 04:04 PM |
| Redmile Group, LLC | Director | Sep 16, 2019 | Buy | $17.50 | 857,143 | 15,000,003 | 11,216,809 | Sep 17, 2019, 04:22 PM |
| Nashat Amir | Director | Jul 31, 2019 | Sale | $22.53 | 31,139 | 701,674 | 1,129,554 | Aug 02, 2019, 04:32 PM |
| Nashat Amir | Director | Aug 01, 2019 | Sale | $22.53 | 30,866 | 695,392 | 1,099,772 | Aug 02, 2019, 04:32 PM |
| Nashat Amir | Director | Jul 30, 2019 | Sale | $22.51 | 90,175 | 2,029,560 | 1,159,599 | Jul 30, 2019, 06:25 PM |
| Nashat Amir | Director | Jul 29, 2019 | Sale | $22.50 | 329 | 7,403 | 1,246,609 | Jul 30, 2019, 06:25 PM |
| Nashat Amir | Director | Jul 26, 2019 | Sale | $22.50 | 27,829 | 626,153 | 1,246,926 | Jul 30, 2019, 06:25 PM |
| Nashat Amir | Director | Jul 24, 2019 | Sale | $22.51 | 19,866 | 447,098 | 1,273,778 | Jul 25, 2019, 06:24 PM |
| Nashat Amir | Director | Jul 23, 2019 | Sale | $22.50 | 62,033 | 1,396,053 | 1,292,946 | Jul 25, 2019, 06:24 PM |
| Nashat Amir | Director | Jul 22, 2019 | Sale | $22.52 | 48,704 | 1,097,019 | 1,352,800 | Jul 22, 2019, 05:52 PM |
| Nashat Amir | Director | Jul 19, 2019 | Sale | $22.50 | 1,053 | 23,693 | 1,399,792 | Jul 22, 2019, 05:52 PM |
| Nashat Amir | Director | Jul 18, 2019 | Sale | $22.50 | 21,409 | 481,795 | 1,400,808 | Jul 22, 2019, 05:52 PM |
| Shoemaker Daniel D | Chief Scientific Officer | Jun 27, 2019 | Option Exercise | $2.90 | 12,500 | 36,250 | 148,091 | Jun 28, 2019, 04:02 PM |
| Shoemaker Daniel D | Chief Scientific Officer | Jun 27, 2019 | Sale | $20.21 | 12,500 | 252,610 | 135,591 | Jun 28, 2019, 04:02 PM |
| Wolchko J Scott | President and CEO | May 16, 2019 | Option Exercise | $1.63 | 14,335 | 23,366 | 389,216 | May 17, 2019, 06:27 PM |
| Wolchko J Scott | President and CEO | May 16, 2019 | Sale | $19.37 | 14,335 | 277,684 | 386,918 | May 17, 2019, 06:27 PM |
| Wolchko J Scott | President and CEO | Apr 18, 2019 | Option Exercise | $1.63 | 11,459 | 18,678 | 381,724 | Apr 19, 2019, 04:13 PM |
| Wolchko J Scott | President and CEO | Apr 17, 2019 | Option Exercise | $1.63 | 8,541 | 13,922 | 382,330 | Apr 19, 2019, 04:13 PM |
| Wolchko J Scott | President and CEO | Apr 18, 2019 | Sale | $16.01 | 11,459 | 183,509 | 374,881 | Apr 19, 2019, 04:13 PM |
| Wolchko J Scott | President and CEO | Apr 17, 2019 | Sale | $16.17 | 8,541 | 138,132 | 374,881 | Apr 19, 2019, 04:13 PM |
| Shoemaker Daniel D | Chief Scientific Officer | Mar 28, 2019 | Option Exercise | $2.90 | 12,500 | 36,250 | 148,091 | Mar 29, 2019, 04:01 PM |
| Shoemaker Daniel D | Chief Scientific Officer | Mar 28, 2019 | Sale | $16.94 | 12,500 | 211,702 | 135,591 | Mar 29, 2019, 04:01 PM |
| Wolchko J Scott | President and CEO | Mar 21, 2019 | Option Exercise | $1.63 | 20,000 | 32,600 | 394,881 | Mar 22, 2019, 04:01 PM |
| Wolchko J Scott | President and CEO | Mar 21, 2019 | Sale | $17.61 | 20,000 | 352,160 | 374,881 | Mar 22, 2019, 04:01 PM |
| TAHL CINDY | General Counsel and Secretary | Mar 01, 2019 | Option Exercise | $2.90 | 25,000 | 72,500 | 115,418 | Mar 05, 2019, 09:00 AM |
| TAHL CINDY | General Counsel and Secretary | Mar 01, 2019 | Sale | $16.15 | 25,000 | 403,697 | 90,418 | Mar 05, 2019, 09:00 AM |
| TAHL CINDY | General Counsel and Secretary | Feb 25, 2019 | Option Exercise | $2.90 | 25,000 | 72,500 | 115,418 | Feb 27, 2019, 04:01 PM |
| TAHL CINDY | General Counsel and Secretary | Feb 25, 2019 | Sale | $16.07 | 25,000 | 401,820 | 90,418 | Feb 27, 2019, 04:01 PM |
| Nashat Amir | Director | Jan 30, 2019 | Sale | $14.16 | 53,017 | 750,959 | 1,474,979 | Feb 01, 2019, 05:02 PM |
| Nashat Amir | Director | Jan 29, 2019 | Sale | $14.16 | 97,500 | 1,380,795 | 1,529,622 | Jan 31, 2019, 06:00 PM |
| Nashat Amir | Director | Jan 28, 2019 | Sale | $13.78 | 70,000 | 964,768 | 1,626,157 | Jan 30, 2019, 04:10 PM |
| Nashat Amir | Director | Jan 25, 2019 | Sale | $14.14 | 90,000 | 1,272,753 | 1,696,859 | Jan 29, 2019, 04:31 PM |
| Nashat Amir | Director | Jan 18, 2019 | Sale | $16.28 | 39,483 | 642,834 | 1,785,088 | Jan 23, 2019, 04:32 PM |
| TAHL CINDY | General Counsel and Secretary | Jan 07, 2019 | Option Exercise | $2.27 | 25,000 | 56,673 | 70,418 | Jan 09, 2019, 04:03 PM |
| TAHL CINDY | General Counsel and Secretary | Jan 07, 2019 | Sale | $16.00 | 25,000 | 400,000 | 45,418 | Jan 09, 2019, 04:03 PM |
| Nashat Amir | Director | Dec 20, 2018 | Sale | $12.25 | 33,474 | 410,160 | 1,824,360 | Dec 26, 2018, 04:13 PM |
| Nashat Amir | Director | Dec 19, 2018 | Sale | $13.40 | 91,210 | 1,222,592 | 1,882,881 | Dec 21, 2018, 04:12 PM |
| Nashat Amir | Director | Dec 13, 2018 | Sale | $16.67 | 17,788 | 296,563 | 1,948,494 | Dec 17, 2018, 04:25 PM |
| Nashat Amir | Director | Dec 12, 2018 | Sale | $16.78 | 425,000 | 7,132,690 | 1,980,561 | Dec 14, 2018, 04:33 PM |
| Nashat Amir | Director | Dec 11, 2018 | Sale | $16.71 | 82,528 | 1,379,183 | 2,393,552 | Dec 13, 2018, 05:14 PM |
| Redmile Group, LLC | Director | Sep 25, 2018 | Buy | $13.50 | 3,703,704 | 50,000,004 | 10,359,666 | Sep 27, 2018, 04:23 PM |
| ABBOT STEWART | Chief Development Officer | May 15, 2018 | Option Exercise | $6.62 | 21,054 | 139,411 | 64,917 | May 16, 2018, 05:28 PM |
| Wolchko J Scott | President and CEO | Oct 16, 2017 | Sale | $4.07 | 800 | 3,256 | 124,881 | Oct 17, 2017, 04:05 PM |
| Wolchko J Scott | President and CEO | Oct 13, 2017 | Sale | $3.87 | 16,368 | 63,344 | 125,681 | Oct 17, 2017, 04:05 PM |
| TAHL CINDY | General Counsel and Secretary | Oct 16, 2017 | Sale | $4.10 | 500 | 2,050 | 45,418 | Oct 17, 2017, 04:04 PM |
| TAHL CINDY | General Counsel and Secretary | Oct 13, 2017 | Sale | $3.83 | 7,591 | 29,074 | 45,918 | Oct 17, 2017, 04:04 PM |
| Shoemaker Daniel D | Chief Scientific Officer | Oct 16, 2017 | Sale | $4.08 | 700 | 2,856 | 90,591 | Oct 17, 2017, 04:04 PM |
| Shoemaker Daniel D | Chief Scientific Officer | Oct 13, 2017 | Sale | $3.86 | 12,525 | 48,346 | 91,291 | Oct 17, 2017, 04:04 PM |
| Storgard Chris | Chief Medical Officer | Nov 23, 2016 | Buy | $2.66 | 37,593 | 99,997 | 37,593 | Nov 28, 2016, 03:46 PM |
| RASTETTER WILLIAM H | Director | Nov 23, 2016 | Buy | $2.66 | 375,939 | 999,998 | 459,272 | Nov 28, 2016, 03:44 PM |
| Coughlin Timothy P | Director | Nov 23, 2016 | Buy | $2.66 | 56,390 | 149,997 | 56,390 | Nov 28, 2016, 03:42 PM |
| Wolchko J Scott | President and CEO | Aug 23, 2016 | Option Exercise | $1.37 | 2,570 | 3,521 | 142,049 | Aug 24, 2016, 06:55 PM |
| Wolchko J Scott | President and CEO | Jan 18, 2016 | Option Exercise | $1.50 | 7,500 | 11,238 | 139,479 | Jan 20, 2016, 02:32 PM |
| Wolchko J Scott | See Remarks | Apr 13, 2015 | Option Exercise | $1.47 | 8,000 | 11,723 | 34,773 | Apr 14, 2015, 04:22 PM |
| Weyer Christian | See Remarks | Apr 13, 2015 | Option Exercise | $1.37 | 25,000 | 34,250 | 30,429 | Apr 14, 2015, 03:52 PM |
| Flynn Peter D | See remarks | Jun 11, 2014 | Option Exercise | $1.63 | 1,017 | 1,658 | 5,056 | Jun 12, 2014, 05:45 PM |
| Flynn Peter D | See remarks | Jun 12, 2014 | Option Exercise | $1.61 | 5,471 | 8,808 | 9,510 | Jun 12, 2014, 05:45 PM |
| Flynn Peter D | See remarks | Jun 11, 2014 | Sale | $7.00 | 1,017 | 7,119 | 4,039 | Jun 12, 2014, 05:45 PM |
| Flynn Peter D | See remarks | Jun 12, 2014 | Sale | $7.00 | 5,471 | 38,297 | 4,039 | Jun 12, 2014, 05:45 PM |
| Flynn Peter D | See remarks | Jun 09, 2014 | Option Exercise | $1.63 | 1,260 | 2,054 | 6,645 | Jun 11, 2014, 05:58 PM |
| Flynn Peter D | See remarks | Jun 10, 2014 | Option Exercise | $1.63 | 699 | 1,139 | 5,389 | Jun 11, 2014, 05:58 PM |
| Flynn Peter D | See remarks | Jun 09, 2014 | Sale | $7.00 | 1,955 | 13,685 | 4,690 | Jun 11, 2014, 05:58 PM |
| Flynn Peter D | See remarks | Jun 10, 2014 | Sale | $7.00 | 1,350 | 9,450 | 4,039 | Jun 11, 2014, 05:58 PM |
| Flynn Peter D | See remarks | May 01, 2014 | Option Exercise | $1.62 | 25,341 | 40,977 | 15,178 | May 05, 2014, 05:48 PM |
| Flynn Peter D | See remarks | May 01, 2014 | Sale | $7.07 | 29,379 | 207,598 | 5,385 | May 05, 2014, 05:48 PM |
| Flynn Peter D | See remarks | Apr 04, 2014 | Option Exercise | $1.63 | 5,889 | 9,599 | 12,620 | Apr 07, 2014, 12:39 PM |
| Flynn Peter D | See remarks | Apr 04, 2014 | Sale | $8.00 | 5,889 | 47,109 | 6,831 | Apr 07, 2014, 12:39 PM |
| Wolchko J Scott | See remarks | Apr 03, 2014 | Option Exercise | $1.37 | 8,862 | 12,141 | 23,888 | Apr 07, 2014, 12:32 PM |
| Weyer Christian | See remarks | Apr 02, 2014 | Option Exercise | $1.37 | 2,262 | 3,099 | 2,262 | Apr 03, 2014, 12:55 PM |
| Weyer Christian | See remarks | Apr 01, 2014 | Option Exercise | $1.37 | 7,738 | 10,601 | 7,738 | Apr 03, 2014, 12:55 PM |
| Weyer Christian | See remarks | Apr 02, 2014 | Sale | $9.02 | 2,262 | 20,395 | 0 | Apr 03, 2014, 12:55 PM |
| Weyer Christian | See remarks | Apr 01, 2014 | Sale | $9.02 | 7,738 | 69,789 | 0 | Apr 03, 2014, 12:55 PM |
| Shoemaker Daniel D | Chief Technology Officer | Mar 31, 2014 | Sale | $9.86 | 8,653 | 85,361 | 26,362 | Apr 02, 2014, 12:07 PM |
| Flynn Peter D | See remarks | Mar 31, 2014 | Sale | $10.16 | 2,692 | 27,348 | 8,377 | Apr 02, 2014, 12:00 PM |
| Flynn Peter D | See remarks | Apr 01, 2014 | Sale | $9.05 | 1,346 | 12,177 | 6,731 | Apr 02, 2014, 12:00 PM |
| Wolchko J Scott | See remarks | Apr 01, 2014 | Sale | $9.08 | 4,019 | 36,482 | 15,026 | Apr 02, 2014, 11:52 AM |
| Wolchko J Scott | See remarks | Mar 31, 2014 | Sale | $9.79 | 15,981 | 156,397 | 19,545 | Apr 02, 2014, 11:52 AM |
| VENROCK ASSOCIATES V LP | 10% Owner | Oct 04, 2013 | Option Exercise | $6.00 | 128,447 | 770,682 | 1,639,854 | Oct 07, 2013, 04:18 PM |
| VENROCK ASSOCIATES V LP | 10% Owner | Oct 04, 2013 | Buy | $6.00 | 833,333 | 4,999,998 | 2,473,187 | Oct 07, 2013, 04:18 PM |
| Polaris Venture Management Co. V, L.L.C. | 10% Owner | Oct 04, 2013 | Option Exercise | $6.00 | 1,239 | 7,434 | 1,639,853 | Oct 07, 2013, 02:17 PM |
| Polaris Venture Management Co. V, L.L.C. | 10% Owner | Oct 04, 2013 | Option Exercise | $6.00 | 849 | 5,094 | 1,638,614 | Oct 07, 2013, 02:17 PM |
| Polaris Venture Management Co. V, L.L.C. | 10% Owner | Oct 04, 2013 | Option Exercise | $6.00 | 2,415 | 14,490 | 1,637,765 | Oct 07, 2013, 02:17 PM |
| Polaris Venture Management Co. V, L.L.C. | 10% Owner | Oct 04, 2013 | Option Exercise | $6.00 | 123,943 | 743,658 | 1,635,350 | Oct 07, 2013, 02:17 PM |
| Polaris Venture Management Co. V, L.L.C. | 10% Owner | Oct 04, 2013 | Buy | $6.00 | 5,508 | 33,048 | 2,465,145 | Oct 07, 2013, 02:17 PM |
| Polaris Venture Management Co. V, L.L.C. | 10% Owner | Oct 04, 2013 | Buy | $6.00 | 15,672 | 94,032 | 2,459,637 | Oct 07, 2013, 02:17 PM |
| Polaris Venture Management Co. V, L.L.C. | 10% Owner | Oct 04, 2013 | Buy | $6.00 | 804,112 | 4,824,672 | 2,443,965 | Oct 07, 2013, 02:17 PM |
| Polaris Venture Management Co. V, L.L.C. | 10% Owner | Oct 04, 2013 | Buy | $6.00 | 8,041 | 48,246 | 2,473,186 | Oct 07, 2013, 02:17 PM |
| Nashat Amir | Director | Oct 04, 2013 | Option Exercise | $6.00 | 2,415 | 14,490 | 1,637,765 | Oct 07, 2013, 02:07 PM |
| Nashat Amir | Director | Oct 04, 2013 | Option Exercise | $6.00 | 123,943 | 743,658 | 1,635,350 | Oct 07, 2013, 02:07 PM |
| Nashat Amir | Director | Oct 04, 2013 | Option Exercise | $6.00 | 1,239 | 7,434 | 1,639,853 | Oct 07, 2013, 02:07 PM |
| Nashat Amir | Director | Oct 04, 2013 | Option Exercise | $6.00 | 849 | 5,094 | 1,638,614 | Oct 07, 2013, 02:07 PM |
| Nashat Amir | Director | Oct 04, 2013 | Buy | $6.00 | 8,041 | 48,246 | 2,473,186 | Oct 07, 2013, 02:07 PM |
| Nashat Amir | Director | Oct 04, 2013 | Buy | $6.00 | 5,508 | 33,048 | 2,465,145 | Oct 07, 2013, 02:07 PM |
| Nashat Amir | Director | Oct 04, 2013 | Buy | $6.00 | 15,672 | 94,032 | 2,459,637 | Oct 07, 2013, 02:07 PM |
| Nashat Amir | Director | Oct 04, 2013 | Buy | $6.00 | 804,112 | 4,824,672 | 2,443,965 | Oct 07, 2013, 02:07 PM |
| OVP VENTURE PARTNERS VII LP | 10% Owner | Oct 04, 2013 | Option Exercise | $6.00 | 822 | 4,932 | 1,499,467 | Oct 07, 2013, 02:06 PM |
| OVP VENTURE PARTNERS VII LP | 10% Owner | Oct 04, 2013 | Option Exercise | $6.00 | 116,629 | 699,774 | 1,498,645 | Oct 07, 2013, 02:06 PM |
| ARCH VENTURE FUND VI LP | 10% Owner | Oct 04, 2013 | Option Exercise | $6.00 | 128,447 | 770,682 | 1,639,855 | Oct 07, 2013, 02:06 PM |
| ARCH VENTURE FUND VI LP | 10% Owner | Oct 04, 2013 | Buy | $6.00 | 833,333 | 4,999,998 | 2,473,188 | Oct 07, 2013, 02:06 PM |
| NELSEN ROBERT | Director | Oct 04, 2013 | Option Exercise | $6.00 | 128,447 | 770,682 | 1,639,855 | Oct 07, 2013, 02:00 PM |
| NELSEN ROBERT | Director | Oct 04, 2013 | Buy | $6.00 | 833,333 | 4,999,998 | 2,473,188 | Oct 07, 2013, 02:00 PM |
| RASTETTER WILLIAM H | Director | Oct 04, 2013 | Buy | $6.00 | 83,333 | 499,998 | 83,333 | Oct 07, 2013, 01:59 PM |
| MENDLEIN JOHN | Director | Oct 04, 2013 | Buy | $6.00 | 16,667 | 100,002 | 156,774 | Oct 07, 2013, 01:59 PM |
Load More Insider Transactions
Buy
Sale
Option Exercise
| Owner | Relationship | Date | Value($) |
| Dulac Edward J III | Chief Financial Officer | 03/04/2024 | 19,013 |
| Dulac Edward J III | Chief Financial Officer | 01/29/2024 | 9,245 |
| TAHL CINDY | General Counsel and Secretary | 01/09/2024 | 47,519 |
| Valamehr Bahram | Chief R&D Officer | 01/09/2024 | 49,367 |
| Wolchko J Scott | President and CEO | 01/09/2024 | 62,889 |
| Dulac Edward J III | Chief Financial Officer | 01/09/2024 | 30,712 |
| Dulac Edward J III | Chief Financial Officer | 01/02/2024 | 18,966 |
| Redmile Group, LLC | Director | 12/26/2023 | 12,315,953 |
| Redmile Group, LLC | Director | 12/26/2023 | 166,024 |
| Dulac Edward J III | Chief Financial Officer | 12/18/2023 | 5,548 |
| TAHL CINDY | General Counsel and Secretary | 11/09/2023 | 58,471 |
| Dulac Edward J III | Chief Financial Officer | 08/18/2023 | 13,210 |
| Xu Yuan | Director | 08/04/2023 | 2,345 |
| Powl Brian T. | Chief Commercial Officer | 07/05/2023 | 18,769 |
| Dulac Edward J III | Chief Financial Officer | 07/05/2023 | 25,029 |
| Xu Yuan | Director | 06/14/2023 | 19,307 |
| Redmile Group, LLC | Director | 04/21/2023 | 1,586,029 |
| Redmile Group, LLC | Director | 04/20/2023 | 119,800 |
| Chu Yu-Waye | Chief Medical Officer | 04/18/2023 | 16,648 |
| Redmile Group, LLC | Director | 04/14/2023 | 64,151,058 |
| Redmile Group, LLC | Director | 04/14/2023 | 154,200 |
| Redmile Group, LLC | Director | 04/14/2023 | 1,765,660 |
| MENDLEIN JOHN | Director | 01/19/2023 | 38,992 |
| MENDLEIN JOHN | Director | 01/13/2023 | 198,906 |
| MENDLEIN JOHN | Director | 01/11/2023 | 499,232 |
| Valamehr Bahram | Chief R&D Officer | 01/12/2023 | 580 |
| Wolchko J Scott | President and CEO | 01/10/2023 | 240,553 |
| Valamehr Bahram | Chief R&D Officer | 01/10/2023 | 57,205 |
| TAHL CINDY | General Counsel and Secretary | 01/10/2023 | 60,538 |
| Plavsic Mark | Chief Technical Officer | 01/10/2023 | 17,910 |
| Dulac Edward J III | Chief Financial Officer | 01/10/2023 | 38,414 |
| Chu Yu-Waye | Chief Medical Officer | 01/10/2023 | 41,003 |
| Dulac Edward J III | Chief Financial Officer | 08/18/2022 | 153,051 |
| Wolchko J Scott | President and CEO | 07/22/2022 | 16,864 |
| Wolchko J Scott | President and CEO | 07/21/2022 | 81,000 |
| Wolchko J Scott | President and CEO | 07/22/2022 | 200,356 |
| Wolchko J Scott | President and CEO | 07/21/2022 | 986,361 |
| Valamehr Bahram | Chief R&D Officer | 07/07/2022 | 46,841 |
| Valamehr Bahram | Chief R&D Officer | 07/07/2022 | 518,686 |
| Valamehr Bahram | Chief R&D Officer | 07/06/2022 | 25,629 |
| Valamehr Bahram | Chief R&D Officer | 07/06/2022 | 235,809 |
| Agarwal Shefali | Director | 06/07/2022 | 18,409 |
| MENDLEIN JOHN | Director | 06/03/2022 | 31,086 |
| Jooss Karin | Director | 06/03/2022 | 33,842 |
| HERSHBERG ROBERT | Director | 06/03/2022 | 15,288 |
| COUGHLIN TIMOTHY | Director | 06/03/2022 | 32,824 |
| Agarwal Shefali | Director | 06/03/2022 | 18,400 |
| TAHL CINDY | General Counsel and Secretary | 06/01/2022 | 163,750 |
| TAHL CINDY | General Counsel and Secretary | 06/01/2022 | 574,000 |
| Wolchko J Scott | President and CEO | 04/21/2022 | 81,000 |
| Wolchko J Scott | President and CEO | 04/22/2022 | 27,000 |
| Wolchko J Scott | President and CEO | 04/22/2022 | 345,911 |
| Wolchko J Scott | President and CEO | 04/21/2022 | 1,049,881 |
| Chu Yu-Waye | Chief Medical Officer | 04/19/2022 | 143,673 |
| Valamehr Bahram | Chief R&D Officer | 03/14/2022 | 68,250 |
| Valamehr Bahram | Chief R&D Officer | 03/14/2022 | 776,733 |
| MENDLEIN JOHN | Director | 03/10/2022 | 51,446 |
| MENDLEIN JOHN | Director | 03/10/2022 | 1,105,200 |
| Wolchko J Scott | President and CEO | 01/20/2022 | 81,000 |
| Wolchko J Scott | President and CEO | 01/21/2022 | 27,000 |
| Wolchko J Scott | President and CEO | 01/20/2022 | 81,900 |
| Wolchko J Scott | President and CEO | 01/21/2022 | 380,200 |
| Wolchko J Scott | President and CEO | 01/20/2022 | 1,206,300 |
| Wolchko J Scott | President and CEO | 01/11/2022 | 709,027 |
| TAHL CINDY | General Counsel and Secretary | 01/11/2022 | 262,975 |
| Valamehr Bahram | Chief R&D Officer | 01/11/2022 | 221,655 |
| Dulac Edward J III | Chief Financial Officer | 01/11/2022 | 85,757 |
| Chu Yu-Waye | Senior VP Clinical Development | 01/11/2022 | 192,340 |
| Wolchko J Scott | President and CEO | 01/10/2022 | 1,600,534 |
| TAHL CINDY | General Counsel and Secretary | 01/10/2022 | 359,313 |
| Valamehr Bahram | Chief R&D Officer | 01/10/2022 | 259,558 |
| TAHL CINDY | General Counsel and Secretary | 01/03/2022 | 327,500 |
| TAHL CINDY | General Counsel and Secretary | 01/03/2022 | 2,966,853 |
| Dulac Edward J III | Chief Financial Officer | 12/20/2021 | 512,802 |
| Dulac Edward J III | Chief Financial Officer | 12/20/2021 | 958,620 |
| Valamehr Bahram | Chief R&D Officer | 12/13/2021 | 68,250 |
| Valamehr Bahram | Chief R&D Officer | 12/13/2021 | 1,191,406 |
| Chu Yu-Waye | Senior VP Clinical Development | 12/10/2021 | 122,400 |
| Chu Yu-Waye | Senior VP Clinical Development | 12/10/2021 | 385,948 |
| Wolchko J Scott | President and CEO | 11/18/2021 | 54,000 |
| Wolchko J Scott | President and CEO | 11/18/2021 | 1,085,400 |
| Wolchko J Scott | President and CEO | 10/22/2021 | 91,670 |
| Wolchko J Scott | President and CEO | 10/21/2021 | 81,900 |
| Wolchko J Scott | President and CEO | 10/22/2021 | 1,766,400 |
| Wolchko J Scott | President and CEO | 10/21/2021 | 1,806,560 |
| TAHL CINDY | General Counsel and Secretary | 10/01/2021 | 327,500 |
| TAHL CINDY | General Counsel and Secretary | 10/01/2021 | 2,941,462 |
| Dulac Edward J III | Chief Financial Officer | 09/28/2021 | 615,384 |
| Dulac Edward J III | Chief Financial Officer | 09/28/2021 | 1,216,834 |
| Valamehr Bahram | Chief Development Officer | 09/13/2021 | 68,250 |
| Valamehr Bahram | Chief Development Officer | 09/13/2021 | 1,657,257 |
| Wolchko J Scott | President and CEO | 08/19/2021 | 96,700 |
| Wolchko J Scott | President and CEO | 08/19/2021 | 1,760,204 |
| Dulac Edward J III | Chief Financial Officer | 08/19/2021 | 306,602 |
| Wolchko J Scott | President and CEO | 07/23/2021 | 124,100 |
| Wolchko J Scott | President and CEO | 07/22/2021 | 81,900 |
| Wolchko J Scott | President and CEO | 07/23/2021 | 2,558,538 |
| Wolchko J Scott | President and CEO | 07/22/2021 | 2,581,575 |
| TAHL CINDY | General Counsel and Secretary | 07/01/2021 | 313,242 |
| TAHL CINDY | General Counsel and Secretary | 07/01/2021 | 4,733,743 |
| Chu Yu-Waye | Senior VP Clinical Development | 04/16/2021 | 272,809 |
| TAHL CINDY | See Remarks | 04/01/2021 | 96,199 |
| TAHL CINDY | See Remarks | 04/01/2021 | 2,514,329 |
| Valamehr Bahram | Chief Development Officer | 03/15/2021 | 72,500 |
| Valamehr Bahram | Chief Development Officer | 03/15/2021 | 2,308,772 |
| Shoemaker Daniel D | Chief Scientific Officer | 03/08/2021 | 2,043,428 |
| Wolchko J Scott | President and CEO | 02/18/2021 | 132,400 |
| Wolchko J Scott | President and CEO | 02/18/2021 | 2,040,256 |
| Wolchko J Scott | President and CEO | 01/21/2021 | 81,900 |
| Wolchko J Scott | President and CEO | 01/22/2021 | 159,700 |
| Wolchko J Scott | President and CEO | 01/22/2021 | 2,948,613 |
| Wolchko J Scott | President and CEO | 01/21/2021 | 3,091,361 |
| TAHL CINDY | General Counsel and Secretary | 01/19/2021 | 101,500 |
| TAHL CINDY | General Counsel and Secretary | 01/19/2021 | 4,016,643 |
| Wolchko J Scott | President and CEO | 01/11/2021 | 951,556 |
| Wolchko J Scott | President and CEO | 01/08/2021 | 7,122,217 |
| Valamehr Bahram | Chief Development Officer | 01/11/2021 | 360,588 |
| Valamehr Bahram | Chief Development Officer | 01/08/2021 | 729,552 |
| TAHL CINDY | General Counsel and Secretary | 01/08/2021 | 729,434 |
| TAHL CINDY | General Counsel and Secretary | 01/11/2021 | 360,587 |
| Shoemaker Daniel D | Chief Scientific Officer | 01/11/2021 | 360,477 |
| Shoemaker Daniel D | Chief Scientific Officer | 01/08/2021 | 729,434 |
| Redmile Group, LLC | Director | 01/08/2021 | 27,999,968 |
| Wolchko J Scott | President and CEO | 12/17/2020 | 132,400 |
| Wolchko J Scott | President and CEO | 12/17/2020 | 1,836,352 |
| Valamehr Bahram | Chief Development Officer | 12/14/2020 | 72,500 |
| Valamehr Bahram | Chief Development Officer | 12/14/2020 | 2,444,477 |
| Shoemaker Daniel D | Chief Scientific Officer | 11/16/2020 | 1,295,746 |
| Wolchko J Scott | President and CEO | 11/12/2020 | 81,900 |
| Wolchko J Scott | President and CEO | 11/13/2020 | 172,007 |
| Wolchko J Scott | President and CEO | 11/12/2020 | 1,581,524 |
| Wolchko J Scott | President and CEO | 11/13/2020 | 1,530,900 |
| TAHL CINDY | General Counsel and Secretary | 11/05/2020 | 54,340 |
| TAHL CINDY | General Counsel and Secretary | 11/04/2020 | 140,647 |
| TAHL CINDY | General Counsel and Secretary | 11/05/2020 | 976,252 |
| TAHL CINDY | General Counsel and Secretary | 11/04/2020 | 2,597,140 |
| TAHL CINDY | General Counsel and Secretary | 10/16/2020 | 79,713 |
| TAHL CINDY | General Counsel and Secretary | 10/16/2020 | 1,467,212 |
| TAHL CINDY | General Counsel and Secretary | 10/01/2020 | 95,550 |
| TAHL CINDY | General Counsel and Secretary | 10/01/2020 | 1,426,065 |
| Valamehr Bahram | Chief Development Officer | 09/14/2020 | 68,778 |
| Valamehr Bahram | Chief Development Officer | 09/14/2020 | 907,024 |
| Shoemaker Daniel D | Chief Scientific Officer | 09/14/2020 | 907,540 |
| Redmile Group, LLC | Director | 06/11/2020 | 39,999,991 |
| RASTETTER WILLIAM H | Director | 03/30/2020 | 38,992 |
| Valamehr Bahram | Chief Development Officer | 02/03/2020 | 1,949 |
| Wolchko J Scott | President and CEO | 01/30/2020 | 67,500 |
| Wolchko J Scott | President and CEO | 01/30/2020 | 636,303 |
| Valamehr Bahram | Chief Development Officer | 01/08/2020 | 117,947 |
| TAHL CINDY | General Counsel and Secretary | 01/08/2020 | 118,085 |
| Shoemaker Daniel D | Chief Scientific Officer | 01/08/2020 | 117,986 |
| Shoemaker Daniel D | Chief Scientific Officer | 12/30/2019 | 72,500 |
| Shoemaker Daniel D | Chief Scientific Officer | 12/30/2019 | 487,427 |
| Wolchko J Scott | President and CEO | 12/19/2019 | 67,500 |
| Wolchko J Scott | President and CEO | 12/20/2019 | 67,500 |
| Wolchko J Scott | President and CEO | 12/20/2019 | 504,157 |
| Wolchko J Scott | President and CEO | 12/19/2019 | 501,897 |
| Wolchko J Scott | President and CEO | 10/15/2019 | 303,458 |
| Valamehr Bahram | Chief Development Officer | 10/15/2019 | 87,891 |
| TAHL CINDY | General Counsel and Secretary | 10/15/2019 | 145,292 |
| Shoemaker Daniel D | Chief Scientific Officer | 10/15/2019 | 168,593 |
| Redmile Group, LLC | Director | 09/16/2019 | 15,000,003 |
| Nashat Amir | Director | 07/31/2019 | 701,674 |
| Nashat Amir | Director | 08/01/2019 | 695,392 |
| Nashat Amir | Director | 07/30/2019 | 2,029,560 |
| Nashat Amir | Director | 07/29/2019 | 7,403 |
| Nashat Amir | Director | 07/26/2019 | 626,153 |
| Nashat Amir | Director | 07/24/2019 | 447,098 |
| Nashat Amir | Director | 07/23/2019 | 1,396,053 |
| Nashat Amir | Director | 07/22/2019 | 1,097,019 |
| Nashat Amir | Director | 07/19/2019 | 23,693 |
| Nashat Amir | Director | 07/18/2019 | 481,795 |
| Shoemaker Daniel D | Chief Scientific Officer | 06/27/2019 | 36,250 |
| Shoemaker Daniel D | Chief Scientific Officer | 06/27/2019 | 252,610 |
| Wolchko J Scott | President and CEO | 05/16/2019 | 23,366 |
| Wolchko J Scott | President and CEO | 05/16/2019 | 277,684 |
| Wolchko J Scott | President and CEO | 04/18/2019 | 18,678 |
| Wolchko J Scott | President and CEO | 04/17/2019 | 13,922 |
| Wolchko J Scott | President and CEO | 04/18/2019 | 183,509 |
| Wolchko J Scott | President and CEO | 04/17/2019 | 138,132 |
| Shoemaker Daniel D | Chief Scientific Officer | 03/28/2019 | 36,250 |
| Shoemaker Daniel D | Chief Scientific Officer | 03/28/2019 | 211,702 |
| Wolchko J Scott | President and CEO | 03/21/2019 | 32,600 |
| Wolchko J Scott | President and CEO | 03/21/2019 | 352,160 |
| TAHL CINDY | General Counsel and Secretary | 03/01/2019 | 72,500 |
| TAHL CINDY | General Counsel and Secretary | 03/01/2019 | 403,697 |
| TAHL CINDY | General Counsel and Secretary | 02/25/2019 | 72,500 |
| TAHL CINDY | General Counsel and Secretary | 02/25/2019 | 401,820 |
| Nashat Amir | Director | 01/30/2019 | 750,959 |
| Nashat Amir | Director | 01/29/2019 | 1,380,795 |
| Nashat Amir | Director | 01/28/2019 | 964,768 |
| Nashat Amir | Director | 01/25/2019 | 1,272,753 |
| Nashat Amir | Director | 01/18/2019 | 642,834 |
| TAHL CINDY | General Counsel and Secretary | 01/07/2019 | 56,673 |
| TAHL CINDY | General Counsel and Secretary | 01/07/2019 | 400,000 |
| Nashat Amir | Director | 12/20/2018 | 410,160 |
| Nashat Amir | Director | 12/19/2018 | 1,222,592 |
| Nashat Amir | Director | 12/13/2018 | 296,563 |
| Nashat Amir | Director | 12/12/2018 | 7,132,690 |
| Nashat Amir | Director | 12/11/2018 | 1,379,183 |
| Redmile Group, LLC | Director | 09/25/2018 | 50,000,004 |
| ABBOT STEWART | Chief Development Officer | 05/15/2018 | 139,411 |
| Wolchko J Scott | President and CEO | 10/16/2017 | 3,256 |
| Wolchko J Scott | President and CEO | 10/13/2017 | 63,344 |
| TAHL CINDY | General Counsel and Secretary | 10/16/2017 | 2,050 |
| TAHL CINDY | General Counsel and Secretary | 10/13/2017 | 29,074 |
| Shoemaker Daniel D | Chief Scientific Officer | 10/16/2017 | 2,856 |
| Shoemaker Daniel D | Chief Scientific Officer | 10/13/2017 | 48,346 |
| Storgard Chris | Chief Medical Officer | 11/23/2016 | 99,997 |
| RASTETTER WILLIAM H | Director | 11/23/2016 | 999,998 |
| Coughlin Timothy P | Director | 11/23/2016 | 149,997 |
| Wolchko J Scott | President and CEO | 08/23/2016 | 3,521 |
| Wolchko J Scott | President and CEO | 01/18/2016 | 11,238 |
| Wolchko J Scott | See Remarks | 04/13/2015 | 11,723 |
| Weyer Christian | See Remarks | 04/13/2015 | 34,250 |
| Flynn Peter D | See remarks | 06/11/2014 | 1,658 |
| Flynn Peter D | See remarks | 06/12/2014 | 8,808 |
| Flynn Peter D | See remarks | 06/11/2014 | 7,119 |
| Flynn Peter D | See remarks | 06/12/2014 | 38,297 |
| Flynn Peter D | See remarks | 06/09/2014 | 2,054 |
| Flynn Peter D | See remarks | 06/10/2014 | 1,139 |
| Flynn Peter D | See remarks | 06/09/2014 | 13,685 |
| Flynn Peter D | See remarks | 06/10/2014 | 9,450 |
| Flynn Peter D | See remarks | 05/01/2014 | 40,977 |
| Flynn Peter D | See remarks | 05/01/2014 | 207,598 |
| Flynn Peter D | See remarks | 04/04/2014 | 9,599 |
| Flynn Peter D | See remarks | 04/04/2014 | 47,109 |
| Wolchko J Scott | See remarks | 04/03/2014 | 12,141 |
| Weyer Christian | See remarks | 04/02/2014 | 3,099 |
| Weyer Christian | See remarks | 04/01/2014 | 10,601 |
| Weyer Christian | See remarks | 04/02/2014 | 20,395 |
| Weyer Christian | See remarks | 04/01/2014 | 69,789 |
| Shoemaker Daniel D | Chief Technology Officer | 03/31/2014 | 85,361 |
| Flynn Peter D | See remarks | 03/31/2014 | 27,348 |
| Flynn Peter D | See remarks | 04/01/2014 | 12,177 |
| Wolchko J Scott | See remarks | 04/01/2014 | 36,482 |
| Wolchko J Scott | See remarks | 03/31/2014 | 156,397 |
| VENROCK ASSOCIATES V LP | 10% Owner | 10/04/2013 | 770,682 |
| VENROCK ASSOCIATES V LP | 10% Owner | 10/04/2013 | 4,999,998 |
| Polaris Venture Management Co. V, L.L.C. | 10% Owner | 10/04/2013 | 7,434 |
| Polaris Venture Management Co. V, L.L.C. | 10% Owner | 10/04/2013 | 5,094 |
| Polaris Venture Management Co. V, L.L.C. | 10% Owner | 10/04/2013 | 14,490 |
| Polaris Venture Management Co. V, L.L.C. | 10% Owner | 10/04/2013 | 743,658 |
| Polaris Venture Management Co. V, L.L.C. | 10% Owner | 10/04/2013 | 33,048 |
| Polaris Venture Management Co. V, L.L.C. | 10% Owner | 10/04/2013 | 94,032 |
| Polaris Venture Management Co. V, L.L.C. | 10% Owner | 10/04/2013 | 4,824,672 |
| Polaris Venture Management Co. V, L.L.C. | 10% Owner | 10/04/2013 | 48,246 |
| Nashat Amir | Director | 10/04/2013 | 14,490 |
| Nashat Amir | Director | 10/04/2013 | 743,658 |
| Nashat Amir | Director | 10/04/2013 | 7,434 |
| Nashat Amir | Director | 10/04/2013 | 5,094 |
| Nashat Amir | Director | 10/04/2013 | 48,246 |
| Nashat Amir | Director | 10/04/2013 | 33,048 |
| Nashat Amir | Director | 10/04/2013 | 94,032 |
| Nashat Amir | Director | 10/04/2013 | 4,824,672 |
| OVP VENTURE PARTNERS VII LP | 10% Owner | 10/04/2013 | 4,932 |
| OVP VENTURE PARTNERS VII LP | 10% Owner | 10/04/2013 | 699,774 |
| ARCH VENTURE FUND VI LP | 10% Owner | 10/04/2013 | 770,682 |
| ARCH VENTURE FUND VI LP | 10% Owner | 10/04/2013 | 4,999,998 |
| NELSEN ROBERT | Director | 10/04/2013 | 770,682 |
| NELSEN ROBERT | Director | 10/04/2013 | 4,999,998 |
| RASTETTER WILLIAM H | Director | 10/04/2013 | 499,998 |
| MENDLEIN JOHN | Director | 10/04/2013 | 100,002 |
Load More Insider Transactions
FUNDS WITH A POSITION IN FATE THERAPEUTICS INC
| Fund | # Shares Owned | % of Portfolio | % Change | Investing Style |
|---|---|---|---|---|
| BLACKROCK INC. | 11,212,816 | 0.00107% | -10.19% | Other |
| D. E. SHAW & CO., INC. | 3,581,979 | 0.01% | -23.98% | Other |
| GEODE CAPITAL MANAGEMENT, LLC | 1,863,485 | 0.00073% | 4.96% | Other |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | 1,700,000 | 0.01% | New | Other |
| ORBIMED ADVISORS LLC | 528,080 | 0.04% | New | Other |
| AQR CAPITAL MANAGEMENT LLC | 235,058 | 0.00165% | -29.39% | Other |
| BRUCE & CO., INC. | 143,000 | 0.19% | -28.5% | Value |
| ROYCE & ASSOCIATES LP | 107,318 | 0.00371% | 253.73% | Value |
| BALYASNY ASSET MANAGEMENT L.P. | 39,836 | 0.00028% | -72.74% | Event Driven |
CHANGE IN SHARES OUTSTANDING FOR FATE THERAPEUTICS INC
STOCK BUYBACKS FOR FATE THERAPEUTICS INC
Period of Report
Previous Period
% Change in Shares
10-K/10-Q Filings
Quarter
Load More
Period of Report: 12/31/2023
10-K/10-Q Filings: View
Previous Period
% Change in Shares
Quarter
09/30/2023
0.05%
1Q
06/30/2023
0.22%
2Q
03/31/2023
0.57%
3Q
12/31/2022
1.43%
4Q
09/30/2022
1.64%
5Q
06/30/2022
1.98%
6Q
03/31/2022
2.36%
7Q
12/31/2021
2.94%
8Q
09/30/2021
3.36%
9Q
06/30/2021
4.55%
10Q
03/31/2021
5.55%
11Q
12/31/2020
12.84%
12Q
09/30/2020
13.50%
13Q
06/30/2020
24.35%
14Q
03/31/2020
29.95%
15Q
12/31/2019
30.31%
16Q
Load More
BUYBACK ANNOUNCEMENT(S) FOR FATE THERAPEUTICS INC
LOADING...